Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JUST IN: $OXFD Oxford Immunotec Reports Third Quarter 2020 Financial Results
Third quarter revenue of $ 19.4 million, above guidance of range of $18 - $ 19 million Asia-Pacific region returns to g r owth and sets a new quarterly sales record for the region Europe & rest of world and U.S....
News: $OXFD Oxford Immunotec Reports Second Quarter 2019 Financial Results
Second quarter revenue of $19.6 million, an increase of 18% compared to prior year period Gross margin of 72.4%, reflecting our shift towards a pure-play kit business Positive net income of $0.6 million compared to a net loss of $6.5 million in prior year period OXFORD, United K...
Aug. 15, 2017 9:13 AM ET|About: Oxford Immunotec Globa... (OXFD)|By: Douglas W. House, SA News Editor
•Oxford Immunotec (NASDAQ:OXFD) prices its public offering of 2.5M ordinary shares at $16.05 per share yielding gross proceeds of $40.125M. Underwriters over-allotment is an additional 375K shares. Closing date is August 18.
•Yesterday's close was $17.33.
•Now read: Omeros' OMS721 continues to demonstrate treatment benefit after one year in IgA nephropathy patients; shares ahead 5% »